Skip To Content

Study ID: Merck MK-3475-355 Keynote 355 Breast Cancer

Title:

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer ¿ (KEYNOTE-355)

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Amy Sanford, MD,Amit Panwalkar, MD
Disease:
Breast - Invasive
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.